Clinical Cancer Research Impact Factor

The first signal is journal position. CCR is not a generic cancer journal. It is one of the more established translational and clinical oncology owners in the AACR portfolio.

The second signal is durability. The five-year JIF of 11.2 is slightly higher than the current JIF, which suggests the strongest papers keep being cited beyond the short initial window.

The third signal is profile cleanliness. The JIF without self-cites is 10.0, essentially the same as the headline JIF. That tells you the current number is not being meaningfully inflated by internal citation habits.

The JCI of 2.36 also matters. Oncology has uneven citation density across basic mechanism papers, biomarker work, immunotherapy, and clinical trial reporting. A JCI above 2 says the journal is performing well even after field normalization.

The JCR row above is the authoritative impact factor on this page. For the longer directional view, the table below uses the open Scopus-based impact score series as a trend proxy.

Directionally, the open citation signal is down from 9.00 in 2023 to 8.53 in 2024, and down further from the 2021 peak. That looks less like journal weakness and more like a post-peak normalization after a very active oncology citation period.

The healthier read is that CCR still holds a stable upper-tier translational position. The cycle cooled, but the journal did not lose its editorial role.

The common mistake is to see a double-digit JIF and assume that any good oncology paper with a clinical paragraph in the discussion should fit.

That is not how the journal defines itself. CCR is unusually explicit that it wants work that bridges the laboratory and the clinic.

In practice, that usually means:

• a believable translational line, not just translational language
• biomarkers or mechanisms tied to treatment, response, or resistance logic
• clinical relevance that is visible before the discussion section
• a package that can speak to translational oncology readers rather than only one narrow basic-science niche

That means the metric confirms the journal is strong. It does not confirm that the bridge in your manuscript is strong enough.

In our pre-submission review work on manuscripts targeting Clinical Cancer Research, the repeat problem is translational overclaim.

The paper often says the right words, but the actual figures do not yet carry the bridge from molecular finding to patient consequence.

In our pre-submission review work on manuscripts targeting CCR, four failure patterns recur.

The translational claim lives in prose, not data. Editors notice quickly when the bridge is mostly rhetorical.

The work is too basic. Mechanistic cancer biology without a believable clinical line of sight often belongs elsewhere.

The work is too purely clinical. Some clinical datasets are useful, but they still lack the translational architecture CCR prefers.

The relevance arrives too late. If the abstract and first figure sequence do not surface the bridge early, the package reads softer than it is.

If that sounds familiar, a Clinical Cancer Research submission readiness check is usually more useful than another round of language polishing.

The impact factor does not tell you whether the translational bridge is credible enough, whether the biomarker story is actionable enough, or whether the best owner is a more mechanistic or more clinically centered journal.

That is where most mismatches happen. The metric places the journal. It does not strengthen the bridge.